GO:0098736 negative regulation of the force of heart contraction: Physiological Braking, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0098736 describes any biological process that decreases the force of heart muscle contraction, acting as a physiological brake on cardiac inotropy.
• The term is a biological_process child of the broader regulation of heart contraction, and it is distinct from positive inotropic regulation and from heart rate control.
• Negative inotropy is achieved through reduced myofilament calcium sensitivity, altered myosin regulatory light chain phosphorylation, and autonomic/cholinergic signaling.
• Key molecular players include MYH6, MYH7, MYL2, MYL3, TNNT2, TNNI3, ACTC1, TPM1, MYBPC3, TTN, PLN, ATP2A2, CACNA1C, KCNQ1, and ADRB1.
• Dysregulation of negative inotropic pathways contributes to heart failure with preserved ejection fraction (HFpEF), hypertrophic cardiomyopathy, and arrhythmias.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of candidate genes in negative regulation of contraction force.
Description
The Gene Ontology term GO:0098736, negative regulation of the force of heart contraction, defines any process that decreases the force of heart muscle contraction. This biological process is fundamental to cardiac physiology because the heart must dynamically tune its inotropic state on a beat-to-beat basis to match circulatory demand, and excessive contractile force can be as detrimental as insufficient force. Researchers study this term to understand how the myocardium brakes contraction, how that braking fails in disease, and how to therapeutically modulate it.
negative regulation of the force of heart contraction At A Glance
| GO ID | GO:0098736 |
|---|---|
| GO term | negative regulation of the force of heart contraction |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the force of heart muscle contraction |
| Parent term | regulation of the force of heart contraction |
| Related process | regulation of heart contraction |
| Cellular context | Cardiac myocytes, myofilaments, sarcoplasmic reticulum, sarcolemma |
| Physiological role | Beat-to-beat tuning of inotropy and prevention of hypercontractility |
What Is GO:0098736?
In plain terms, GO:0098736 captures all biological mechanisms that make the heart squeeze less forcefully. It is a biological_process term whose definition is any process that decreases the force of heart muscle contraction. This includes reduced calcium sensitivity of the myofilaments, inhibitory phosphorylation of contractile proteins, and neural or humoral signals that suppress inotropy.
Why Is negative regulation of the force of heart contraction Important in Cell Biology?
Negative regulation of the force of heart contraction is essential for cardiac homeostasis because it prevents excessive energy consumption, protects against diastolic dysfunction, and allows the heart to relax adequately between beats. When this process is impaired, the myocardium can become hypercontractile or stiff, contributing to hypertrophic cardiomyopathy, HFpEF, and arrhythmogenesis. Understanding the genes and signaling pathways that mediate negative inotropy is therefore central to cardiovascular drug discovery and to interpreting genetic variants in sarcomeric proteins.
• Maintains diastolic filling by limiting excessive systolic force.
• Prevents myocardial energy depletion during stress.
• Modulates myofilament calcium sensitivity through phosphorylation of TNNI3 and MYL2.
• Mediates cholinergic and vagal braking of cardiac contractility.
• Contributes to the pathophysiology of HFpEF and hypertrophic cardiomyopathy.
• Provides a target for negative inotropic drugs such as beta-blockers and calcium channel blockers.
• Influences arrhythmia susceptibility by altering repolarization-contraction coupling.
• Guides interpretation of sarcomeric gene variants in inherited cardiomyopathies.
• Enables CRISPR-based causal testing of candidate negative inotropic genes.
• Supports development of precision therapeutics for contractile dysfunction.
What Happens During negative regulation of the force of heart contraction?
Autonomic and Humoral Inputs
In simple terms: Nerves and hormones tell the heart to squeeze less hard.
Negative regulation of contraction force begins with inhibitory signals such as vagal acetylcholine and circulating catecholamine withdrawal, which reduce cAMP and PKA activity in cardiac myocytes. In teleost and mammalian hearts, autonomic nerves and circulating catecholamines directly modulate contractile force, establishing the neurohumoral basis of negative inotropy.
Calcium Handling and Myofilament Sensitivity
In simple terms: Less calcium available or less sensitivity to calcium means weaker contraction.
Reduced sarcoplasmic reticulum calcium release and decreased myofilament calcium sensitivity lower the force of contraction. Phosphorylation of troponin I (TNNI3) and myosin regulatory light chain (MYL2) by kinases such as PKC and PKA decreases calcium sensitivity and cross-bridge cycling, directly implementing negative regulation of contraction force.
Myosin Regulatory Light Chain and Sarcomeric Tuning
In simple terms: Chemical tags on myosin change how strongly it pulls.
The myosin regulatory light chain and myosin heavy chain isoforms tune the force and kinetics of the sarcomere. Zone-specific regulation of cardiac myosin and its phosphorylation state determines whether the myofilament generates more or less force, and dephosphorylation or inhibitory phosphorylation contributes to negative regulation of contraction force.
Titin Phosphorylation and Passive Stiffness
In simple terms: The spring-like titin protein can be tuned to make the heart stiffer or softer.
Titin hyperphosphorylation alters passive stiffness and contraction-regulating protein expression in HFpEF models, and interventions that counteract titin hyperphosphorylation can restore normal contractile regulation. This demonstrates that negative regulation of contraction force is coupled to titin-based mechanosignaling and post-translational modification.
Myocardial Delamination and Trabeculation
In simple terms: Early heart muscle cells must delaminate to build the inner heart surface, and this process is mechanically coupled to contraction.
Mechanically activated snai1b coordinates the initiation of myocardial delamination for trabeculation, linking contractile force regulation to developmental morphogenesis. Perturbation of this mechanotransduction pathway alters the force of contraction and downstream trabecular patterning, providing an in vivo context for negative regulation of contraction force.
Key Genes Involved in GO:0098736 negative regulation of the force of heart contraction
The following genes and proteins are experimentally implicated in negative regulation of the force of heart contraction or in the sarcomeric and signaling machinery that executes it.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MYH6 | Alpha myosin heavy chain; cross-bridge cycling | Target for negative inotropic modulation |
| MYH7 | Beta myosin heavy chain; slow cross-bridge kinetics | Hypertrophic cardiomyopathy variant studies |
| MYL2 | Myosin regulatory light chain; calcium sensitivity | Phosphorylation-dependent force regulation |
| MYL3 | Myosin essential light chain; sarcomere assembly | Structural basis of contractile tuning |
| TNNT2 | Troponin T; thin filament regulation | Sarcomeric cardiomyopathy modeling |
| TNNI3 | Troponin I; inhibitory subunit; PKC/PKA substrate | Negative inotropy via reduced calcium sensitivity |
| ACTC1 | Cardiac actin; thin filament | Contractile force studies |
| TPM1 | Tropomyosin; thin filament regulation | Calcium sensitivity modulation |
| MYBPC3 | Myosin binding protein C; cross-bridge modulation | HFpEF and HCM research |
| TTN | Titin; passive stiffness and mechanosignaling | Titin hyperphosphorylation in HFpEF |
| PLN | Phospholamban; SERCA2a inhibitor | Calcium handling and negative inotropy |
| ATP2A2 | SERCA2a; calcium reuptake | Contraction-relaxation coupling |
| CACNA1C | L-type calcium channel; calcium influx | Excitation-contraction coupling |
| KCNQ1 | Potassium channel; repolarization | Arrhythmia and contractile coupling |
| ADRB1 | Beta-1 adrenergic receptor; cAMP signaling | Autonomic control of inotropy |
| CHRM2 | Muscarinic receptor; vagal braking | Cholinergic negative inotropy |
| SNai1b | Mechanically activated transcription factor | Myocardial delamination and trabeculation |
How Is negative regulation of the force of heart contraction Regulated?
Negative regulation of the force of heart contraction is itself regulated by phosphorylation cascades, calcium handling, and mechanotransduction. Beta-adrenergic signaling increases cAMP and PKA activity to enhance contraction, so withdrawal of this input or activation of muscarinic receptors reduces force. PKC-mediated phosphorylation of TNNI3 and MYL2 decreases myofilament calcium sensitivity, providing a direct molecular brake. Titin phosphorylation status modulates passive stiffness and contraction-regulating protein expression, and its dysregulation is linked to HFpEF. Mechanically activated transcription factors such as snai1b couple contraction force to developmental gene expression.
negative regulation of the force of heart contraction and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TTN | HFpEF; titin hyperphosphorylation | Rat HFpEF model with MyoMed205 intervention |
| MYH7 | Hypertrophic cardiomyopathy | Knock-in mouse or iPSC-derived cardiomyocytes |
| TNNI3 | Cardiomyopathy; altered calcium sensitivity | Point-mutation knock-in in hiPSCs |
| KCNQ1 | Long QT syndrome; arrhythmia | CRISPR knockout in cardiomyocytes |
| SNai1b | Myocardial delamination and trabeculation | Zebrafish knockout and mechanotransduction assays |
Heart Failure with Preserved Ejection Fraction (HFpEF)
HFpEF is characterized by impaired relaxation and altered contractile regulation, and titin hyperphosphorylation together with changes in contraction-regulating proteins contributes to the phenotype. Targeting negative inotropic pathways may restore normal diastolic function.
Hypertrophic Cardiomyopathy (HCM)
Mutations in sarcomeric genes such as MYH7, MYBPC3, TNNT2, and TNNI3 alter force generation and calcium sensitivity, disrupting negative regulation of contraction force. These variants are a major cause of inherited cardiomyopathy and sudden cardiac death.
Arrhythmias and Channelopathies
Ion channel genes including KCNQ1 and CACNA1C influence repolarization and calcium influx, which in turn affect contractile force regulation. Dysregulation of these pathways can promote arrhythmogenesis.
Neuromuscular and Autonomic Disorders
Muscle satellite cell dysfunction in neuromuscular disorders can indirectly affect cardiac muscle homeostasis and contractile regulation. Autonomic dysfunction alters the balance of positive and negative inotropic signaling.
From negative regulation of the force of heart contraction-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase contraction force? | CRISPR knockout in hiPSC-derived cardiomyocytes |
| Does a sarcomeric variant alter calcium sensitivity? | Point-mutation knock-in in hiPSCs |
| Does a regulatory phosphorylation site control inotropy? | Phospho-mutant knock-in mouse |
| Can a therapeutic protein restore negative inotropy? | Overexpression in rat HFpEF model |
| How does mechanotransduction regulate trabeculation? | Zebrafish snai1b knockout |
| Does autonomic input modulate force in vivo? | Teleost or mammalian autonomic nerve stimulation |
How to Study the negative regulation of the force of heart contraction Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular calcium transients | Assessing negative inotropy in cardiomyocytes |
| Traction force microscopy | Contractile force at single-cell level | Testing sarcomeric variants |
| Phosphoproteomics | Phosphorylation of contractile proteins | Identifying negative inotropic modifications |
| RNA-seq | Gene expression changes | HFpEF and mechanotransduction studies |
| Echocardiography | In vivo contractility and relaxation | Animal models of heart failure |
| Pressure-volume loops | Hemodynamic force and stiffness | HFpEF phenotyping |
| Western blotting | Protein expression and phosphorylation | Validating titin and TNNI3 changes |
| CRISPR screening | Causal gene identification | Discovering negative regulators of contraction |
Calcium Imaging and Contractility Assays
Calcium transient measurements and traction force microscopy in cardiomyocytes quantify the force of contraction and its negative regulation. These assays are used to test sarcomeric variants and drug responses.
Phosphoproteomics and Western Blotting
Phosphoproteomics identifies phosphorylation events on TNNI3, MYL2, and titin that mediate negative inotropy. Western blotting with phospho-specific antibodies validates these changes in animal models.
Transcriptomics and RNA-seq
RNA-seq reveals changes in contraction-regulating protein expression in HFpEF and other disease models. It can also identify downstream targets of mechanotransduction pathways such as snai1b.
In Vivo Hemodynamic and Echocardiographic Assessment
Echocardiography and pressure-volume loop analysis measure contractility and relaxation in vivo, providing functional readouts of negative regulation of contraction force.
How CRISPR Can Be Used to Study GO:0098736 negative regulation of the force of heart contraction
Knockout
CRISPR knockout of candidate genes such as KCNQ1 or MYL2 in cardiomyocytes can test whether loss of function increases contraction force, thereby identifying negative regulators. Knockout models are also used in zebrafish to study snai1b-dependent delamination.
Point Mutation
Point-mutation knock-in of sarcomeric variants (e.g., in MYH7 or TNNI3) allows precise testing of how single amino acid changes alter calcium sensitivity and force regulation. This is critical for interpreting clinical variants of uncertain significance.
Knock-in
Knock-in of phospho-mimetic or phospho-deficient alleles at regulatory sites in MYL2 or TNNI3 can dissect the role of phosphorylation in negative inotropy. Tagged knock-in of titin or MYBPC3 enables live-cell imaging of sarcomere dynamics.
Overexpression
Overexpression of negative regulators such as phospholamban or a therapeutic protein like MyoMed205 can reduce contraction force and counteract hyperphosphorylation in HFpEF models. Overexpression in hiPSC-derived cardiomyocytes provides a human-relevant platform.
How EDITGENE Supports negative regulation of the force of heart contraction Research
Researchers studying negative regulation of the force of heart contraction-related genes often need to determine whether a candidate gene is causally involved in reducing contractile force or is merely a bystander. EDITGENE provides the CRISPR tools and bioinformatics support to answer these questions rigorously.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of the force of heart contraction research.
Frequently Asked Questions About negative regulation of the force of heart contraction
What is negative regulation of the force of heart contraction?
It is the biological process (GO:0098736) that decreases the force of heart muscle contraction, involving reduced calcium sensitivity and inhibitory signaling.
What genes are involved in negative regulation of the force of heart contraction?
Key genes include TNNI3, MYL2, PLN, ATP2A2, CHRM2, and TTN, among others.
How does phosphorylation regulate heart contraction force?
Phosphorylation of TNNI3 and MYL2 by PKC or PKA reduces myofilament calcium sensitivity and cross-bridge cycling, decreasing force.
What is the role of titin in heart contraction force?
Titin phosphorylation alters passive stiffness and contraction-regulating protein expression, and its hyperphosphorylation is linked to HFpEF.
Which diseases involve impaired negative regulation of heart contraction?
HFpEF, hypertrophic cardiomyopathy, and arrhythmias are associated with dysregulated negative inotropy.
How can CRISPR help study negative regulation of heart contraction?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in cardiomyocytes.
What methods measure the force of heart contraction?
Calcium imaging, traction force microscopy, echocardiography, and pressure-volume loops are commonly used.
What is the role of the autonomic nervous system in heart contraction force?
Vagal acetylcholine and catecholamine withdrawal reduce cAMP and PKA activity, decreasing contractile force.
What is the difference between positive and negative regulation of heart contraction?
Positive regulation increases force, while negative regulation decreases force; both are essential for cardiac homeostasis.
Can negative regulation of heart contraction be targeted therapeutically?
Yes, interventions such as MyoMed205 that counteract titin hyperphosphorylation show promise in HFpEF models.
Conclusion
GO:0098736 negative regulation of the force of heart contraction is a critical biological process that protects the heart from excessive contractile force and energy depletion. Its molecular basis involves calcium handling, sarcomeric phosphorylation, and mechanotransduction, with key roles for TNNI3, MYL2, TTN, and PLN. Dysregulation of this process contributes to HFpEF, hypertrophic cardiomyopathy, and arrhythmias, making it a prime target for therapeutic intervention.
References
- 1. Ganassi M et al.. 2022. Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. Eur J Transl Myol 32(1) PMID: 35302338
- 4. Wang J et al.. 2025. Mechanically activated snai1b coordinates the initiation of myocardial delamination for trabeculation.. Nat Commun 16(1):8363 PMID: 40993149
- 5. Nelson SR. 2025. Resolving zone-specific regulation of cardiac myosin.. J Gen Physiol 157(6) PMID: 40876855
- 6. Vahle B et al.. 2025. MyoMed205 Counteracts Titin Hyperphosphorylation and the Expression of Contraction-Regulating Proteins in a Rat Model of HFpEF.. J Cachexia Sarcopenia Muscle 16(3):e13843 PMID: 40464169
- 7. Langer GA. 1977. Ionic basis of myocardial contractility.. Annu Rev Med 28:13-20 PMID: 324352
- 8. Holmgren S. 1977. Regulation of the heart of a teleost, Gadus morhua, by autonomic nerves and circulating catecholamines.. Acta Physiol Scand 99(1):62-74 PMID: 842366
